International Journal of Hypertension

Review Article

Statins: Cardiovascular Risk Reduction in Percutaneous Coronary Intervention—Basic and Clinical Evidence of Hyperacute Use of Statins

Table 1

Randomized trials with statins in percutaneous coronary intervention. This table is a summary of the 8 randomized trials (versus placebo or versus control groups) published with statins in individuals under PCI. All studies except Vaselka's have shown positive results for the use of statins prior to PCI. The results in individuals with elevated before PCI (NAPLES II) and in individuals with ACS (ARMYDA-ACS y ARMYDA-RECAPTURE, ACS soubgroup), are particularly favorable. MI-PCI-A: Myocardial Infarction-PCI associated. MACE: Mayor Adverse Cardiovascular Events. MRI: Myocardial Reperfusion Indicators.
TrialInterventional scenarioTreatmentPrimary end point
ARMYDA-Original
N 153 naive (76/77)		Non-ACSAtorvastatin versus placebo 40 mg/7 days pre-PCI↓ MI-PCI-A. CPK-MB > 2x ULN 05.0% versus 18.0% ( )
NAPLES I
N 451 naive (226/225)		Non-ACSVarious statins versus control
Different doses >72 hr pre-PCI		↓ MI-PCI-A. CPK-MB > 3x ULN 08.0% versus 15.6% ( )
NAPLES II
N 668 naive (338/330)		Non-ACSAtorvastatin versus control 80 mg/24 hr pre-PCI↓ MI-PCI-A. CPK-MB > 3x ULN 09.5% versus 15.8% ( )
↓ MI-PCI-A. CPK-MB > 3x ULN 04.6% versus 16.5% ( ) (subgroup > 6 mg/lt)
ARMYDA-ACS
N 171 naive (85/86)		Non-STEMI ACSAtorvastatin versus placebo 120 mg/12 hr pre-PCI↓ MACE day 30. 05.0% versus 17.0% ( )
↓ MI-PCI-A. CPK-MB > 2x ULN 0.5% versus 15.0% ( )
ARMYDA-REC
N 383 preTx (192/191)		Non-STEMI ACS 47%Non-ACS 53%Atorvastatin versus placebo 120 mg/12 hr pre-PCI↓ MACE day 30. 03.7% versus 09.4% ( ).
↓ MACEs day 30. 03.3% versus 14.8% ( ) (subgroup ACS)
Non-STEMI Korean
N 445 naive (220/225)		Non-STEMI ACSRosuvastatin versus control 40 mg/16 hr pre-PCI↓ MI-PCI-A. CPK-MB > 2x ULN. 05.8% versus 11.4% ( ).
STEMI Korean
N 171 naive (86/85)		STEMI ACSAtorvastatin high versus low dose 80 mg versus 10 mg in primary PCI↓ MACE day 30. 05.8% versus 10.6% ( )
↑ MRIs min 90 after PCI. All indicators
Vaselka
N 200 naive (100/100)		Non-ACSAtorvastatin versus Control 80 mg/48 hr pre-PCI↓ MI-PCI-A. CPK-MB > 3x ULN 10.0% versus 12.0% ( )